141834-14-2

Basic information

• Product Name: ETHYL (2S)-2-(([4-(BROMOMETHYL)PHENYL]SULFONYL)AMINO)-4-METHYLPENTANOATE
• Synonyms: ETHYL (2S)-2-(([4-(BROMOMETHYL)PHENYL]SULFONYL)AMINO)-4-METHYLPENTANOATE
• CAS NO: 141834-14-2
• Molecular Formula: C₁₅H₂₂BrNO₄S
• Molecular Weight: 392.31
• Mol File: 141834-14-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL (2S)-2-(([4-(BROMOMETHYL)PHENYL]SULFONYL)AMINO)-4-METHYLPENTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL (2S)-2-(([4-(BROMOMETHYL)PHENYL]SULFONYL)AMINO)-4-METHYLPENTANOATE(141834-14-2)
• EPA Substance Registry System: ETHYL (2S)-2-(([4-(BROMOMETHYL)PHENYL]SULFONYL)AMINO)-4-METHYLPENTANOATE(141834-14-2)

Safety Data

• Hazardous Substances Data: 141834-14-2(Hazardous Substances Data)

Upstream product

• 2743-60-4 L-Leucine ethyl ester 
• 2743-40-0 L-leucine ethyl ester hydrochloride 
• 66176-39-4 4-(bromomethyl)benzene-1-sulfonyl chloride 

Downstream Products

• 141834-17-5 N-4-azidomethylphenylsulphonyl-L-leucine ethyl ester 
• 141834-23-3 N-ethoxycarbonylmethyl-N-4-bromomethylphenylsulphonyl-L-leucine ethyl ester 
• 141834-16-4 N-methyl-N-4-bromomethylphenylsulphonyl-L-leucine ethyl ester 
• 141834-27-7 N-ethoxycarbonyl-N-4-bromomethylphenylsulphonyl-L-leucine ethyl ester 

Relevant articles and documents

Heterocyclic sulfonamide derivatives as antagonists of PAF and angiotensin II

Compounds of formula (I), wherein: A represents: a) a --VR6 group wherein v is --C(=O), --C(=O)O--, --CH2 O--, --CH2 OC(=O)--, --C(=S)--, --CH2 OC(=O)NH--, --C(=S)O--, --CH2 S--, --C(=O)NHSO2 --, --SO2 NHC(=O)-- or --CH2 OSiPh2 --; b) a --CH2 NR9 R10 group or a --CONR9 R10 group wherein each of R9 and R10 is independently hydrogen, -alkyl-, -alkenyl-, -alkynyl, -cycloalkyl, -cycloalkenyl, pyridyl (any of which may optionally be substituted) or a group --D as defined above or R9 and R10 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring; c) a group Y where Y is a 5- or 6-membered optionally substituted heterocyclic ring containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; or d) a group --CH2 Y or --C(=O)NHY; where Y is as defined above; B represents a 5- or 6-membered heterocyclic ring containing one or more nitrogen atoms in its ring, are antagonists of platelet activating factor (PAF) and/or antagonists of angiotensin II.

4-(1H-2-methylimidazo[4,5-c]pyridinylmethyl)phenylsulphonamide derivatives as antagonist of PAF

The present invention is directed to compounds of general formula I as well their pharmaceutically and veterinarily acceptable acid addition salts or hydrates thereof. The present invention is further directed to pharmaceutical and veterinary compositions containing the compounds of general formula I. The present compounds of general formula I are antagonist of platelet activating factor (PAF). Accordingly, the present invention is also directed to methods for preventing, treating or ameliorating in human or mammalian animals, various diseases or physiological conditions mediated by PAF.

Imidazo (4,5-C) pyridine derivatives as PAF antagonists

Compounds of formula I: STR1 wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and B are variables. These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.